US Pharma MarketingMRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration
MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
As MRD shifts from prognostic marker to intervention trigger, sponsors must rethink trial design, endpoints and decision-making.
Source: FierceBiotech